|
1
|
National Cancer Institute, . SEER cancer
statistics factsheets: Anal Cancer. Available from:. http://seer.cancer.gov/statfacts/html/anus.htmlJun
7–2021
|
|
2
|
Bartelink H, Roelofsen F, Eschwege F,
Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M and
Pierart M: Concomitant radiotherapy and chemotherapy is superior to
radiotherapy alone in the treatment of locally advanced anal
cancer: Results of a phase III randomized trial of the European
organization for research and treatment of cancer radiotherapy and
gastrointestinal cooperative groups. J Clin Oncol. 15:2040–2049.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oliveira SC, Moniz CM, Riechelmann R, Alex
AK, Braghirolli MI, Bariani G, Nahas C and Hoff PM: Phase II study
of capecitabine in substitution of 5-FU in the chemoradiotherapy
regimen for patients with localized squamous cell carcinoma of the
anal canal. J Gastrointest Cancer. 47:75–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peiffert D, Tournier-Rangeard L, Gérard
JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X,
Bouché O, Luporsi E, et al: Induction chemotherapy and dose
intensification of the radiation boost in locally advanced anal
canal carcinoma: Final analysis of the randomized UNICANCER ACCORD
03 trial. J Clin Oncol. 30:1941–1948. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rao S, Guren MG, Khan K, Brown G, Renehan
AG, Steigen SE, Deutsch E, Martinelli E and Arnold D; ESMO
Guidelines Committee. Electronic address, : simpleclinicalguidelines@esmo.org:
Anal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up*. Ann Oncol. 32:1087–1100. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Glynne-Jones R, Sebag-Montefiore D,
Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ,
Stewart J, Beare S, et al: Best time to assess complete clinical
response after chemoradiotherapy in squamous cell carcinoma of the
anus (ACT II): A post-hoc analysis of randomised controlled phase 3
trial. Lancet Oncol. 18:347–356. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chapet O, Gerard JP, Riche B, Alessio A,
Mornex F and Romestaing P: Prognostic value of tumor regression
evaluated after first course of radiotherapy for anal canal cancer.
Int J Radiat Oncol Biol Phys. 63:1316–1324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gerard JP, Ayzac L, Hun D, Romestaing P,
Coquard R, Ardiet JM and Mornex F: Treatment of anal canal
carcinoma with high dose radiation therapy and concomitant
fluorouracil-cisplatinum. Long-term results in 95 patients.
Radiother Oncol. 46:249–256. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ang KK, Harris J, Wheeler R, Weber R,
Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C,
et al: Human papillomavirus and survival of patients with
oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ragin CC and Taioli E: Survival of
squamous cell carcinoma of the head and neck in relation to human
papillomavirus infection: Review and meta-analysis. Int J Cancer.
121:1813–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rischin D, Young RJ, Fisher R, Fox SB, Le
QT, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM and
McArthur GA: Prognostic significance of p16INK4A and human
papillomavirus in patients with oropharyngeal cancer treated on
TROG 02.02 phase III trial. J Clin Oncol. 28:4142–4148. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lewis JS Jr: p16 Immunohistochemistry as a
standalone test for risk stratification in oropharyngeal squamous
cell carcinoma. Head Neck Pathol. 6 (Suppl 1):S75–S82. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Urgoiti GB, Gustafson K, Klimowicz AC,
Petrillo SK, Magliocco AM and Doll CM: The prognostic value of HPV
status and p16 expression in patients with carcinoma of the anal
canal. PLoS One. 9:e1087902014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
NCCN, . NCCN Guidelines for Anal Cancer
Version 1.2024. https://www.nccn.org/professionals/physician_gls/pdf/anal_blocks.pdfMarch
4–2024
|
|
15
|
Lampejo T, Kavanagh D, Clark J, Goldin R,
Osborn M, Ziprin P and Cleator S: Prognostic biomarkers in squamous
cell carcinoma of the anus: A systematic review. Br J Cancer.
103:1858–1869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gillison ML, Chaturvedi AK, Anderson WF
and Fakhry C: Epidemiology of human papillomavirus-positive head
and neck squamous cell carcinoma. J Clin Oncol. 33:3235–3242. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Balachandran S and Narendran A: The
developmental origins of cancer: A review of the genes expressed in
embryonic cells with ımplications for tumorigenesis. Genes (Basel).
14:6042023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Doroshow DB, Bhalla S, Beasley MB, Sholl
LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS and Hirsch FR:
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Nat Rev Clin Oncol. 18:345–362. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wessely A, Heppt MV, Kammerbauer C, Steeb
T, Kirchner T, Flaig MJ, French LE, Berking C, Schmoeckel E and
Reinholz M: Evaluation of PD-L1 expression and HPV genotyping in
anal squamous cell carcinoma. Cancers (Basel). 12:25162020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Balermpas P, Martin D, Wieland U,
Rave-Fränk M, Strebhardt K, Rödel C, Fokas E and Rödel F: Human
papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer
patients treated with chemoradiotherapy: Rationale for
immunotherapy. Oncoimmunology. 6:e12883312017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao YJ, Sun WP, Peng JH, Deng YX, Fang
YJ, Huang J, Zhang HZ, Wan DS, Lin JZ and Pan ZZ: Programmed
death-ligand 1 expression correlates with diminished CD8+ T cell
infiltration and predicts poor prognosis in anal squamous cell
carcinoma patients. Cancer Manag Res. 10:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goodman KA, Gollub M, Eng C, Brierley J,
Palefsky J, Gress D, Williams A and Goldberg R: Anus: AJCC Cancer
Staging Manual. 9th edition. Washington MK: American College of
Surgeons; 2022
|
|
23
|
Glynne-Jones R, Nilsson PJ, Aschele C, Goh
V, Peiffert D, Cervantes A and Arnold D; ESMO; ESSO; ESTRO, : Anal
cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis,
treatment and follow-up. Radiother Oncol. 111:330–339. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kachnic LA, Winter K, Myerson RJ, Goodyear
MD, Willins J, Esthappan J, Haddock MG, Rotman M, Parikh PJ, Safran
H and Willett CG: RTOG 0529: A phase 2 evaluation of dose-painted
intensity modulated radiation therapy in combination with
5-fluorouracil and mitomycin-C for the reduction of acute morbidity
in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys.
86:27–33. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gilbert DC, Williams A, Allan K, Stokoe J,
Jackson T, Linsdall S, Bailey CM and Summers J: p16INK4A, p53, EGFR
expression and KRAS mutation status in squamous cell cancers of the
anus: Correlation with outcomes following chemo-radiotherapy.
Radiother Oncol. 109:146–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang Y, Forslund A, Remotti H, Lönnroth C,
Andersson M, Brevinge H, Svanberg E, Lindnér P, Hafström L, Naredi
P and Lundholm K: P53 mutations in primary tumors and subsequent
liver metastases are related to survival in patients with
colorectal carcinoma who undergo liver resection. Cancer.
91:727–736. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Ruiter EJ, Mulder FJ, Koomen BM, Speel
EJ, van den Hout MFCM, de Roest RH, Bloemena E, Devriese LA and
Willems SM: Comparison of three PD-L1 immunohistochemical assays in
head and neck squamous cell carcinoma (HNSCC). Mod Pathol.
34:1125–1132. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Northover J, Glynne-Jones R,
Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M and
Ledermann J: Chemoradiation for the treatment of epidermoid anal
cancer: 13-year follow-up of the first randomised UKCCCR anal
cancer trial (ACT I). Br J Cancer. 102:1123–1128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
James RD, Glynne-Jones R, Meadows HM,
Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen
S, Leslie M, et al: Mitomycin or cisplatin chemoradiation with or
without maintenance chemotherapy for treatment of squamous-cell
carcinoma of the anus (ACT II): A randomised, phase 3, open-label,
2×2 factorial trial. Lancet Oncol. 14:516–524. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ajani JA, Wang X, Izzo JG, Crane CH, Eng
C, Skibber JM, Das P and Rashid A: Molecular biomarkers correlate
with disease-free survival in patients with anal canal carcinoma
treated with chemoradiation. Dig Dis Sci. 55:1098–1105. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Soares PC, Abdelhay ES, Thuler LCS, Soares
BM, Demachki S, Ferro GVR, Assumpção PP, Lamarão LM, Pinto LF and
Burbano RMR: HPV positive, wild type TP53, and p16 overexpression
correlate with the absence of residual tumors after
chemoradiotherapy in anal squamous cell carcinoma. BMC
Gastroenterol. 18:302018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu DW, El-Mofty SK and Wang HL: Expression
of p16, Rb, and p53 proteins in squamous cell carcinomas of the
anorectal region harboring human papillomavirus DNA. Mod Pathol.
16:692–699. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mai S, Welzel G, Ottstadt M, Lohr F,
Severa S, Prigge ES, Wentzensen N, Trunk MJ, Wenz F, von
Knebel-Doeberitz M and Reuschenbach M: Prognostic relevance of HPV
ınfection and p16 overexpression in squamous cell anal cancer. Int
J Radiat Oncol Biol Phys. 93:819–827. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Foster CC, Lee AY, Furtado LV, Hart J,
Alpert L, Xiao SY, Hyman NH, Sharma MR and Liauw SL: Treatment
outcomes and HPV characteristics for an institutional cohort of
patients with anal cancer receiving concurrent chemotherapy and
intensity-modulated radiation therapy. PLoS One. 13:e01942342018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baricevic I, He X, Chakrabarty B, Oliver
AW, Bailey C, Summers J, Hampson L, Hampson I, Gilbert DC and
Renehan AG: High-sensitivity human papilloma virus genotyping
reveals near universal positivity in anal squamous cell carcinoma:
Different implications for vaccine prevention and prognosis. Eur J
Cancer. 51:776–785. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yhim HY, Lee NR, Song EK, Kwak JY, Lee ST,
Kim JH, Kim JS, Park HS, Chung IJ, Shim HJ, et al: The prognostic
significance of tumor human papillomavirus status for patients with
anal squamous cell carcinoma treated with combined
chemoradiotherapy. Int J Cancer. 129:1752–1760. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rödel F, Wieland U, Fraunholz I, Kitz J,
Rave-Fränk M, Wolff HA, Weiss C, Wirtz R, Balermpas P, Fokas E and
Rödel C: Human papillomavirus DNA load and p16INK4a expression
predict for local control in patients with anal squamous cell
carcinoma treated with chemoradiotherapy. Int J Cancer.
136:278–288. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Serup-Hansen E, Linnemann D,
Skovrider-Ruminski W, Høgdall E, Geertsen PF and Havsteen H: Human
papillomavirus genotyping and p16 expression as prognostic factors
for patients with American Joint Committee on cancer stages I to
III carcinoma of the anal canal. J Clin Oncol. 32:1812–1817. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Neal CP, Garcea G, Doucas H, Manson MM,
Sutton CD, Dennison AR and Berry DP: Molecular prognostic markers
in resectable colorectal liver metastases: A systematic review. Eur
J Cancer. 42:1728–1743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun Y, Wang Z, Qiu S and Wang R:
Therapeutic strategies of different HPV status in head and neck
squamous cell carcinoma. Int J Biol Sci. 17:1104–1118. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ganly I, Soutar DS, Brown R and Kaye SB:
p53 alterations in recurrent squamous cell cancer of the head and
neck refractory to radiotherapy. Br J Cancer. 82:392–398. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meulendijks D, Tomasoa NB, Dewit L, Smits
PH, Bakker R, van Velthuysen ML, Rosenberg EH, Beijnen JH,
Schellens JH and Cats A: HPV-negative squamous cell carcinoma of
the anal canal is unresponsive to standard treatment and frequently
carries disruptive mutations in TP53. Br J Cancer. 112:1358–1366.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cacheux W, Rouleau E, Briaux A, Tsantoulis
P, Mariani P, Richard-Molard M, Buecher B, Dangles-Marie V, Richon
S, Lazartigues J, et al: Mutational analysis of anal cancers
demonstrates frequent PIK3CA mutations associated with poor outcome
after salvage abdominoperineal resection. Br J Cancer.
114:1387–1394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mireștean CC, Iancu RI and Iancu DPT: p53
modulates radiosensitivity in head and neck cancers-from classic to
future horizons. Diagnostics (Basel). 12:30522022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu C, Mann D, Sinha UK and Kokot NC: The
molecular mechanisms of increased radiosensitivity of HPV-positive
oropharyngeal squamous cell carcinoma (OPSCC): An extensive review.
J Otolaryngol Head Neck Surg. 47:592018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bruyere D, Monnien F, Colpart P, Roncarati
P, Vuitton L, Hendrick E, Lepinoy A, Luquain A, Pilard C, Lerho T,
et al: Treatment algorithm and prognostic factors for patients with
stage I–III carcinoma of the anal canal: A 20-year multicenter
study. Mod Pathol. 34:116–130. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Allal AS, Waelchli L and Bründler MA:
Prognostic value of apoptosis-regulating protein expression in anal
squamous cell carcinoma. Clin Cancer Res. 9:6489–6496.
2003.PubMed/NCBI
|
|
49
|
Zhu X, Jamshed S, Zou J, Azar A, Meng X,
Bathini V, Dresser K, Strock C, Yalamarti B, Yang M, et al:
Molecular and immunophenotypic characterization of anal squamous
cell carcinoma reveals distinct clinicopathologic groups associated
with HPV and TP53 mutation status. Mod Pathol. 34:1017–1030. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Armstrong SA, Malley R, Wang H, Lenz HJ,
Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Hwang JJ, Philip PA, et
al: Molecular characterization of squamous cell carcinoma of the
anal canal. J Gastrointest Oncol. 12:2423–2437. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Iseas S, Golubicki M, Robbio J, Ruiz G,
Guerra F, Mariani J, Salanova R, Cabanne A, Eleta M, Gonzalez JV,
et al: A clinical and molecular portrait of non-metastatic anal
squamous cell carcinoma. Transl Oncol. 14:1010842021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chan AM, Urgoiti GR, Jiang W, Lee S,
Kornaga E, Mathen P, Yeung R, Enwere EK, Box A, Konno M, et al: The
prognostic impact of PD-L1 and CD8 expression in anal cancer
patients treated with chemoradiotherapy. Front Oncol.
12:10002632022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen C, Liu Y and Cui B: Effect of
radiotherapy on T cell and PD-1/PD-L1 blocking therapy in tumor
microenvironment. Hum Vaccin Immunother. 17:1555–1567. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Qin Y, Luan J, Zhou X and Li Y: PD-L1
expression in anogenital and oropharyngeal squamous cell carcinomas
associated with different clinicopathological features, HPV status
and prognosis: A meta-analysis. Biosci Rep. 41:BSR202036692021.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Stier EA, Chigurupati NL and Fung L:
Prophylactic HPV vaccination and anal cancer. Hum Vaccin
Immunother. 12:1348–1351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Skolnik JM and Morrow MP: Vaccines for
HPV-associated diseases. Mol Aspects Med. 94:1012242023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Garolla A, Graziani A, Grande G, Ortolani
C and Ferlin A: HPV-related diseases in male patients: An
underestimated conundrum. J Endocrinol Invest. 47:261–274. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
de Bakker T, Journe F, Descamps G, Saussez
S, Dragan T, Ghanem G, Krayem M and Van Gestel D: Restoring p53
function in head and neck squamous cell carcinoma to ımprove
treatments. Front Oncol. 11:7999932022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hamza A, Masliah-Planchon J, Neuzillet C,
Lefèvre JH, Svrcek M, Vacher S, Bourneix C, Delaye M, Goéré D,
Dartigues P, et al: Pathogenic alterations in PIK3CA and KMT2C are
frequent and independent prognostic factors in anal squamous cell
carcinoma treated with salvage abdominoperineal resection. Int J
Cancer. 154:504–515. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Mao W, Li W and Hu X: Tumor hyperthermia
research progress and application prospect in tumoroids (Review).
Mol Clin Oncol. 20:312024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ott OJ, Schmidt M, Semrau S, Strnad V,
Matzel KE, Schneider I, Raptis D, Uter W, Grützmann R and Fietkau
R: Chemoradiotherapy with and without deep regional hyperthermia
for squamous cell carcinoma of the anus. Strahlenther Onkol.
195:607–614. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Telarovic I, Wenger RH and Pruschy M:
Interfering with tumor hypoxia for radiotherapy optimization. J Exp
Clin Cancer Res. 40:1972021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ugwueze CV, Ogamba OJ, Young EE, Onyenekwe
BM and Ezeokpo BC: Metformin: A possible option in cancer
chemotherapy. Anal Cell Pathol (Amst). 27:71809232020.PubMed/NCBI
|
|
64
|
Liu J, Wu J, Chen T, Yang B, Liu X, Xi J,
Zhang Z, Gao Y and Li Z: Enhancing X-Ray sensitization with
multifunctional nanoparticles. Small. 26:e24009542024. View Article : Google Scholar : PubMed/NCBI
|
